Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Pharmacology > Exam 1 > Flashcards

Exam 1 Flashcards

1
Q

Schedule I

A
  • highest potential for abuse
  • NO accepted medical use in US or lacks safety for use in tx in US
  • eg) heroin, marijuana
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Schedule II

A
  • high potential for abuse
  • HAS a currently accepted medical use
  • abuse may lead to severe psychological or physical dependence
  • eg opiates (morphine, oxycodone, methadone), amphetamines (ritalin, adderall), cocaine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Schedule IV

A
  • currently accepted medical use in US
  • abuse may lead to limited physical or psychological dependencies relative to III
  • benzos
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Schedule III

A
  • less abuse potential than I or II
  • accepted medical use
  • abuse may lead to moderate/low physical dependence or high psychological dependence
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Schedule V

A
  • low potential for abuse

- some can be sold in limited amounts without rx

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Where to look for Drug Information

A

lexi-comp, MICROMEDEX, package, URI pharm library

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Where do drugs come from (4)?

A

-plants/natural products, synthetic, semi-synthetic, human pool

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Drug Testing Phases (7)

A
  • compound discovery/”bench”
  • animal phase
  • Human phase I, II, III
  • FDA approval with patent
  • human phase IV (post-marketing phase)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Human Phase I

A
  • determine effects, safe dosage, pharmacokinetics

- small number (<1 year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Human Phase II

A
  • assess drugs effectiveness in treating a specific disease/disorder
  • limited number (200-300) with target disorder
  • 2 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Human phase III

A
  • assess safety and effectiveness in larger pt population
  • large number (1000-3000)
  • double/single blinding, placebo controls
  • 3 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Human phase IV (post-marketing phase)

A
  • monitor any problems after NDA approval
  • general pt population
  • indefinite
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Pharmacotherapeutics

A

-area of pharm that refers to use of specific drugs to prevent, treat, or diagnose a disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Pharmacokinetics

A

-how body deals with drugs in terms of absorption, distribution, metabolism, excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Pharmacodynamics

A
  • what the drug does to the body

- biochemical and physiological effects and mechanism of action

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Enteral methods

A

-oral, sublingual/buccal, rectal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Parenteral methods

A

-inhalation, injection, topical, transdermal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Drug Absorption

A

entrance of drug into bloodstream

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Drug factors affecting absorption (5)

A

-dosage form, drug water solubility, drug lipid solubility, drug particle size, drug concentration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Physiologic factors affecting absorption

A

-biologic/cell membranes, body “compartments”, cell membrane phospholipid bilayer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Lipid Bilayer

A
  • hydrophilic tails, hydrophobic tails
  • SMALL, UNCHARGED particles will pass
  • small/charged and large/uncharged will not
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Bioavailability

A

percentage of administered dose that is absorbed into systemic circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Factors affecting bioavailability (5)

A
  • how administered
  • where administered
  • drug properties
  • properties of the environment
  • additional barriers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

ADME

A

Absorption
Distribution
Metabolism
Excretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Distribution

A

-after drug gains access to bloodstream, it is distributed to the organ/tissues of the body

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Factors affecting Drug distribution (4)

A
  • tissue permeability
  • blood flow
  • binding to plasma proteins
  • binding to subcellular components
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

BBB

A
  • additional lipid barrier that protects the brain by restricting the passage of electrolytes and similar water soluble substances
  • drugs must have a certain degree of lipid solubility to penetrate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

Most likely to penetrate BBB?

A
  • small, uncharged, lipophilic

- eg) heroin, alcohol, benzo, meth

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Plasma protein binding

A
  • plasma proteins (esp albumin) assist in transport of hormones and vitamins
  • only the UNBOUND portion of the drug is able to exert pharmacologic activity. remainder will continue to circulate
  • 80% of most drugs will bind at some level
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Blood Flow

A
  • diff parts of body receive diff amounts of blood

- liver, kidney, heart, and brain have largest blood supply, therefore exposed to largest amount of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Volume of Distribution (Vd)

A
  • Vd = amount administered / plasma concentration
  • not physical volume, refers to size of compartment necessary to account for total amount of the drug in the body if it were present throughout in the same concentration found in plasma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Drugs that are activated with metabolism are called ______.

A

Pro-drugs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Kidney prefers ___ , _____ molecules

A

ionized, water soluble

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Biotransformation

A

chemical aleration of drugs and foreign compounds in the body (phase I)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

DMMS function

A

takes lipid-soluble drugs and prepares for excretion via renal system

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

First-pass effect

A
  • drugs taken orally are absorbed through GI tract into portal circulation. Drug goes to liver BEFORE body. many drugs are inactivated by liver
  • if drug is significantly metabolized, can reduce amount of active drug that reaches circulation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

enzyme induction

A

when used repetitively, some drugs may increase enzyme activity. This may lead to faster metabolism of the drug and shorter duration of action (eg barbituates)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

enzyme inhibition

A

will slow metabolism of all other drugs metabolized by the enzyme system and increase duration and intensity of drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

common pathways of drug excretion

A

-kidney/renal, liver/hepatic, lungs/pulmonary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Clearance (CL)

A
  • ability of the body to remove drug from blood or plasma
  • expressed as volume per unit time (eg ml/min)
  • amount of drug removed depends on plasma concentration as well as clearance
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

entero-hepatic recirculation

A
  • drug secreted into bile, may go into feces

- some drugs reabsorbed, process may be repeated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

periodic measurements of plasma levels can help establish ________ for the drug

A

therapeutic range

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

plasma half-life (t 1/2)

A

time required for the plasma concentration of a given drug to fall to 1/2 its original level
-dependent on CL and Vd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Why is establishing half-life important?

A

kidney and liver disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Loading dose

A
  • try to get the person into therapeutic range quickly
  • many drugs require loading dose to do this effectively
  • a large initial dose of a substance or series of such doses given to rapidly achieve a therapeutic concentration in the body
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Maintenance Dose

A
  • the amount of drug required to keep a desired mean steady-state concentration in the tissues
  • usually drop from loading dose to maintenance dose
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Median Effective Dose (ED50)

A

-dose required to produce a specific therapeutic response in 50% of a group of patients

48
Q

Median Lethal Dose (LD50)

A

-the dose that causes lethality in 50% of a group of animals

49
Q

Therapeutic Index (TI)

A

TI = LD50/ED50

50
Q

Potency

A
  • measure of strength

- more potent drug requires lower dose to produce same effect as a higher dose of the second drug

51
Q

Maximal Efficacy

A

-point at which there is no further increase in response even if dosage continues to be increased

52
Q

Factors that influence drug response

A

-age, height, weight, gender, body fat, genetics, emotional state, placebo effect, presence of disease, patient compliance

53
Q

Pregnancy and drugs

A
  • fetus is exposed to drugs taken during pregnancy
  • placenta is NOT a drug barrier
  • harmful drugs = teratogens
54
Q

Passive exposure

A

-drugs passed from breast milk to infant

55
Q

Difference in Pediatric populations

A

-thinner skin, less skeletal muscle, higher % body water, lower body fat, higher percentage of unbound drug due to reduced plasma protein levels

56
Q

Physiology of Aging

A

–decreased CO –> decreased blood flow
-reduced gastric acid secretion, motility, and intestinal absorption
-lean body mass and total body water decrease, % body fat increases
-decreased renal blood flow
-increased bioavailability of oral drugs
= reduced rate of metabolism, increase in duration of drug action

57
Q

SNS origin

A

T1-L2/3

58
Q

PSNS origin

A

Midbrain, medulla, sacral spinal cord

59
Q

Autonomic Ganglia

A

contain synapses between pre- and post-ganglionic neurons

60
Q

ACh

A
  • in ALL autonomic ganglia

- in effector junction of PSNS

61
Q

ACh synthesized in the _____ from ____ and ____ by _____

A

in the NEURON from ACETYL CoA and CHOLINE, by CHOLINE ACETYLTRANSFERASE
*one step synthesis, synthesized as needed, choline reabsorbed. not used as a drug

62
Q

ACh broken down in the ____ or ______ by ______

A

in the GANGLIONIC JUNCTION or NEURO-EFFECTOR JUNCTION by ACETYLCHOLINE ESTERASE

63
Q

NE is the neurotransmitter at _______

A

NEUROEFFECTOR JUNCTION OF SNS

64
Q

NE belongs to group of endogenous chemicals called ______, which also include ____ and _____

A

CATECHOLAMINES which include EPINEPHRINE and DOPAMINE

65
Q

NE is re-uptaken by the ______, a process mediated by pre-synaptic _______.

A

PRE-SYNAPTIC FIBER, mediated by A2 RECEPTORS (receptor gives signal to decrease NE synthesis = feedback inhibitor)

66
Q

Other mechanisms of inactivation of NE (2)

A
  • breakdown by monoamine oxidase (MAO)

- breakdown by catechol-O-methyltransferase (COMT)

67
Q

M receptors – location

A

-at neuro-effector junction of PSNS

68
Q

N receptors – location (2)

A

-autonomic ganglia (SNS and PSNS) and neuro-muscular junction

69
Q

A1

A

arteriolar smooth muscles –> vasoconstriction

70
Q

A2

A

pre-ganglionic synapse and in CNS

-activation leads to decrease in SNS flow from CNS (decreased NE production)

71
Q

Parasympathomimetics

A

mimic effects of PSNS nerve stimulation

72
Q

Direct acting parasympathomimetics

A

=muscarinic receptor agonists

  • stimulation of M receptors at neuro-effector junction with little or no N receptor stimulation
  • eg) metacholine, carbachol, bethanchol, pilocarpine
73
Q

Indirect Acting parasympathomimetics

A

=prolong action of endogenous ACH by inhibiting ACh esterase (prevent breakdown of ACh)

  • Carbamates eg) -stigmines
  • all are REVERSIBLE inhibtors of esterase -used for same reasons as direct acting, also – myasthenia gravis, paralytic ileus, dementia (aricept)
74
Q

Irreversible ACh esterase inhibitors

A
  • insecticides, nerve gas
  • NO therapeutic use
  • intoxication sx increased secretions, tremors, respiratory collapse
  • atropine, pralidoxime given to counteract
75
Q

Toxic reactions to muscarinic agonists

A
  • treated with atropine sulfate

- epinephrine can help overcome cardiovascular or bronchoconstrictor response

76
Q

Parasympatholytics: Muscarinic Receptor Antagonists

A
  • competitive blocking of M receptors at neuro-effector sites on smooth muscle, cardiac muscle, gland cells, and in CNS
  • little effect on ACh at N receptors
  • given when poisoned by agonists to stimulate heart, bronchodilators
77
Q

M Antagonists - heart

A

increased heart rate by blocking vagal nerve effects on M2 receptors on SA nodal pacemaker

78
Q

M Antagonists - vessels

A
  • only work with choline esters

- block vasodilation

79
Q

M Antagonists - respiratory

A
  • induce bronchodilation

- inhibit secretions of nose, pharynx, and bronchii thus drying mucous membrane of the respiratory tract

80
Q

M Antagonists - GI

A
  • ihibit GI motility and secretions

- inhibit gastric acis secretion

81
Q

M Antagonists - Urinary

A

-decrease tone and amplitude of contractions of ureter and bladder

82
Q

M Antagonists - Sweat glands

A
  • inhibition of sweating, skin becomes hot and dry

- high doses may raise body temp

83
Q

M Antagonists - CNS (atropine and scopolamine)

A
  • only effect if drug crosses BBB
  • Atropine at higher doses (>10mg) causes central excitation, leading to restlessness, hallucinations, delerium. followed by CNS depression - drowsiness, anemia, fatigue
  • Scopolamine - therapeutic doses case SN depression - drowsiness, anemia, fatigure
84
Q

M Antagonist - eye

A

mydriasis and cycloplegia

85
Q

M Antagonist - Principal Use

A

-bronchodilator in COPD, asthma (atrovent)

86
Q

Sympathomimetic Agents

A
  • direct stimulation of adrenergic receptors

- endogenous ones: NE, E, dopamine

87
Q

E - cardiac

A

-through B1, stimulates heart

88
Q

E - respiratory

A

-through B2 - bronchodilate

89
Q

Rapid intravenous injection of E can cause

A

cerebral hemorrhage from sharp rise in BP

-also, tremor, palpation, anxiety, restlessness

90
Q

E - therapeutic uses

A
  • rapid relief of hypersensitivity reactions including anaphylaxis
  • restore cardiac rhythym in pt with cardiac arrest
91
Q

NE - effects

A
  • more powerful activator of A1 than E, but much weaker activator of B2
  • increases BP much more than E (E doesn’t affect BP due to balance of A1/B2)
  • not useful as bronchodilator
92
Q

A1 major effect

A

vasoconstriction

93
Q

A2 major effect

A

decreased SNS activity

94
Q

B1 major effect

A

stimulate heart

95
Q

B2 major effect

A

vasodilation, bronchodilation

96
Q

NE – clinical use

A

limited, can be used for hypotension

97
Q

Dopamine - effects

A
  • central NT and can act as agonist on its own receptor
  • Low doses: D1 receptors in renal, coronary, mesenteric beds can lead to vasodilation
  • High doses: stimulates cardiac B2 - stim heart
98
Q

Dopamine - therapeutic uses

A
  • severe CHF

- dilates renal arteres, increased renal perfusion, increased urine output (= decreased fluid retention)

99
Q

B-Agonists - non selective

A
  • Isopretrenol, Isuprel
  • increased cardiac output (contractility, HR) and dilation of muscle and mesenteric arteries
  • used in emergencies to stimulate HR in pt with bradycardia or heart block
100
Q

B2 selective Agonists

A

-asthma

101
Q

B2 selective agonists - short acting

A
  • rapid onset of action (15 min) and short duration (4-6 hours)
  • albuterol, terbutaline
102
Q

B2 selective agonists - long acting

A

-duration up to 12 hours (salmeterol)

103
Q

A1 selective agonists

A
  • nasal decongestants in pt with allergic rhinitis - constriction of blood vessels in nasal tissues
  • chronic use bad - lost efficacy, worse sx
104
Q

A2 selective agonists

A
  • clonidine*

- stimulates a2 receptors in CNS – decreased CNS sympathetic outflow = tx of HTN

105
Q

Miscellanious Adrenergic Agonists

A
  • dexedrine, ritalin
  • CNS stimulant - release NE in CNS
  • ADHD
106
Q

Beta-blockers main functions (3) and Alpha-blocker main function (1)

A

Bblocker – arrythmia, CHF, HTN

Ablocker – HTN

107
Q

A-adrenoceptor blockers

A
  • *Phentolamines and Tolazoline are non-selective reversible a-blockers
  • Phentolamine used in short term to control HTN in pts with pheocromocytoma (tumor of adrenal glands)
  • Tolazoline used to treat persistent pulmonary HTN in newborns
108
Q

A1 Selective Blockers

A
  • blocking of a1 receptors in vascular smooth muscles of arterioles and veins = decreased peripheral resistance
  • less tachycardia than with non-selective a blockers
  • caution with hypotension
  • Used for treatment of primary systemic hypertension
109
Q

A1 Selective Blockers - adverse effects

A
  • first-dose phenomenon = marked postural hypotension and syncope 60-90 mins after first dose
  • because of vasodilating effect, can promote water retention
110
Q

B Blockers - heart

A

-blocking of B1 leads to slowing of HR and decreased contractility

111
Q

B blockers - pulm

A

little effect in normal ppl

-in pt with asthma or COPD, can lead to life-threatening bronchoconstriction

112
Q

B Blockers - peripheral vascular resistance

A
  • blocking of B2 in arteriolar smooth muscle can lead to increase in vascular resistance
  • long term effect of B1 blocker in HTN pt with high circulating renin levels is a reduction in peripheral vascular resistance
113
Q

Non-Selective B-blockers

A
  • reversibly block both B1/B2 with no selectivity

* *Propranolol - angina pectoris, arrthymia, HTN, prevent reinfarction, prevent vascular headache

114
Q

B1 selective blockers

A
  • higher selectivity to B1

- HTN, CHF, angina, MI

115
Q

B1 selective blockers - adverse effects

A
  • in pt w AV conduction defects, can cause life-threatening bradyarrythmias
  • abrupt discontinuation can exacerbate angina, increase risk of MI
116
Q

B2 selective blockers – adverse effects

A

-can worsen bronchoconstriction in asthmatic pt

B1 selective or nonselective produce less bronchoconstriction

Pharmacology (4 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions